Clinical Pipeline

Biocytogen is committed to developing innovative antibody drugs that meet the needs of patients, focusing on oncology, autoimmune, inflammatory, metabolic and and other diseases. Taking full advantage of its unique advantage in innovative drug development, the company now has more than 10 R & D pipelines including monoclonal antibodies, bispecific antibodies, ADC drugs and so on. Our pipeline is supported by a strong clinical development team and abundant clinical resources.

Therapeutic Area

Products

Target

Molecular Format

Indication

Status

News/Press Release

Partner


Oncology
 


YH003 CD40 Monoclonal antibody Solid Tumor Phase 1-Phase 2 Findings From Anti-CD40 Clinical Trials  

Contact us for partnership
 
 
 

YH001 CTLA-4 Monoclonal Antibody Solid Tumor Phase  1-Phase 2 Findings From Anti-CTLA-4 mAb Clinical Trials
YH002 OX40 Monoclonal Antibody Solid Tumor Phase  1
YH004 4-1BB Monoclonal antibody Pre-clinical
YH008 PD-1/CD40 Bi-specific antibody Pre-clinical
YH005 Not Disclosed ADC Pre-clinical   Remegen
YH010 Not Disclosed Bi-specific antibody Discovery    

Contact us for partnership 
 
 
 
 
 

YH006 Not Disclosed Bi-specific antibody Discovery  
Infectious Diseases YH007 SARS-CoV-2 mAb cocktail Pre-clinical RenMab Platform Drives SARS-CoV2 mAb Cocktail Therapy
YH009 RSV Monoclonal antibody Pre-clinical
Pet Oncology
MP001 dog PD-1  Monoclonal antibody IND   
MP002 dog CTLA-4 Monoclonal antibody Pre-clinical  

 

Back to top